BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Judah Frommer does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 CLDXCelldex Therapeutics Inc | Buy | $43.00 | May 2025 | +52.9% | Miss |
| CLDXCelldex Therapeutics Inc | Buy | $46.00 | Mar 2025 | +56.5% | Miss |
 RGNXRegenxbio Inc | Buy | $24.00 | Mar 2025 | +20.9% | Miss |
 GLPGGalapagos NV ADR | Sell | $22.00 | Feb 2025 | −17.0% | Miss |
 FDMT4D Molecular Therapeutics Inc | Sell | $6.00 | Jan 2025 | −47.1% | Hit |
| FDMT4D Molecular Therapeutics Inc | Sell | $8.00 | Nov 2024 | −30.0% | Hit |
| RGNXRegenxbio Inc | Buy | $22.00 | Nov 2024 | +1.0% | Miss |
 BCAXBicara Therapeutics Inc. Common Stock | Buy | $35.00 | Oct 2024 | −7.3% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.